KR20230135637A - 새로운 활성을 갖는 hhla2 결합제 - Google Patents

새로운 활성을 갖는 hhla2 결합제 Download PDF

Info

Publication number
KR20230135637A
KR20230135637A KR1020237028708A KR20237028708A KR20230135637A KR 20230135637 A KR20230135637 A KR 20230135637A KR 1020237028708 A KR1020237028708 A KR 1020237028708A KR 20237028708 A KR20237028708 A KR 20237028708A KR 20230135637 A KR20230135637 A KR 20230135637A
Authority
KR
South Korea
Prior art keywords
hhla2
ser
thr
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237028708A
Other languages
English (en)
Korean (ko)
Inventor
스콧 샤펠
데틀레브 비니스츠키에비치
비얀 에테마드-길버트슨
나드타칸 볼랜드
넬스 닐슨
비앙카 프린츠
Original Assignee
넥스트포인트 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 넥스트포인트 테라퓨틱스, 인코포레이티드 filed Critical 넥스트포인트 테라퓨틱스, 인코포레이티드
Publication of KR20230135637A publication Critical patent/KR20230135637A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Catalysts (AREA)
KR1020237028708A 2021-01-28 2022-01-28 새로운 활성을 갖는 hhla2 결합제 Pending KR20230135637A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142832P 2021-01-28 2021-01-28
US63/142,832 2021-01-28
PCT/US2022/014423 WO2022165258A1 (en) 2021-01-28 2022-01-28 Hhla2 binding agents with novel activity

Publications (1)

Publication Number Publication Date
KR20230135637A true KR20230135637A (ko) 2023-09-25

Family

ID=82652818

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237028708A Pending KR20230135637A (ko) 2021-01-28 2022-01-28 새로운 활성을 갖는 hhla2 결합제

Country Status (11)

Country Link
US (1) US20250270323A1 (https=)
EP (1) EP4284431A4 (https=)
JP (1) JP2024509501A (https=)
KR (1) KR20230135637A (https=)
CN (1) CN116981476A (https=)
AU (1) AU2022214939A1 (https=)
BR (1) BR112023014826A2 (https=)
CA (1) CA3207494A1 (https=)
IL (1) IL304584A (https=)
MX (1) MX2023008182A (https=)
WO (1) WO2022165258A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326764A (en) * 2023-09-08 2026-04-01 Nextpoint Therapeutics Inc Antibody-drug conjugates
CN119841949A (zh) * 2023-10-17 2025-04-18 科辉智药(深圳)新药研究中心有限公司 一种抗人hhla2的纳米抗体及其应用
CN121005781A (zh) * 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 高亲和力b7h7抗体或其抗原结合片段及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280208B2 (en) * 2014-04-30 2019-05-07 Albert Einstein College Of Medicine TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
EA202090003A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
KR20210007959A (ko) * 2018-04-06 2021-01-20 다나-파버 캔서 인스티튜트 인크. Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도

Also Published As

Publication number Publication date
EP4284431A4 (en) 2025-01-15
BR112023014826A2 (pt) 2023-10-03
JP2024509501A (ja) 2024-03-04
AU2022214939A1 (en) 2023-07-20
CN116981476A (zh) 2023-10-31
US20250270323A1 (en) 2025-08-28
IL304584A (en) 2023-09-01
MX2023008182A (es) 2023-09-15
WO2022165258A1 (en) 2022-08-04
EP4284431A1 (en) 2023-12-06
CA3207494A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
JP7153626B2 (ja) 抗ヒト４－１ｂｂ抗体およびその使用
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
US11384144B2 (en) T cell receptor-like antibodies specific for a PRAME peptide
CN109757103B (zh) 针对tim3的抗体及其用途
KR101577843B1 (ko) 인간 ｏｘ４０ 수용체에 대한 결합 분자
TWI290147B (en) Antibodies against insulin-like growth factor I receptor and uses thereof
KR101671039B1 (ko) 항 ｃｘｃｒ4 항체 및 그들의 암의 치료를 위한 용도
CN110204614B (zh) 抗人lag-3单克隆抗体及其制备方法和用途
KR20210040827A (ko) 항 tigit 항체 및 그 용도
HK1232243A1 (zh) 抗-b7-h5抗体及其用途
CN113045669A (zh) 用于肿瘤治疗之方法及抗体组成物
TW200823237A (en) Antibodies to NTB-A
CN114685665A (zh) 抗ox40的全人抗体及其制备方法和用途
KR20230135637A (ko) 새로운 활성을 갖는 hhla2 결합제
CN114901364A (zh) 用于治疗实体癌和血液癌的组合疗法
KR20230009459A (ko) 인간 ceacam1/3/5에 특이적으로 결합하는 신규 항체 및 그의 용도
CN116745325A (zh) Bcma靶向抗体、嵌合抗原受体及其应用
CN115322257B (zh) Bcma靶向抗体、嵌合抗原受体及其应用
US10626183B2 (en) IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof
CN119013309A (zh) 靶向pd-l1和cd40的抗原结合蛋白及其制备和应用
WO2023052541A1 (en) Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy
CN116234909A (zh) Cd40激动剂抗体和使用方法
US20250171533A1 (en) Kir3dl3 inhibitors and immune cell activating agents
CN114933654B (zh) 靶向cd123的抗体、嵌合抗原受体及其用途
AU2018202095B2 (en) Binding Molecules to the Human OX40 Receptor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230823

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250122

Comment text: Request for Examination of Application